For research and educational purposes only. Not medical advice.

Cagrilintide Reference

Educational, not medical advice reference for Cagrilintide: Metabolic, Fat Loss; regulatory status, evidence posture, source review, and schedul…

Reference summary

Lau 2021 Lancet (Phase 2, n=706 adults with overweight or obesity, 26 weeks) tested once-weekly cagrilintide monotherapy at 0.3, 0.6, 1.2, 2.4, and 4.5 mg vs placebo and vs liraglutide 3 mg. The 2.4 mg cagrilintide dose reduced body weight by approximately 9.7 percent from baseline by week 26 (placebo-subtracted treatment difference up to about 7.8 percent), comparable to liraglutide. Cagrilintide is now developed primarily as the amylin component of CagriSema (Garvey 2025 NEJM REDEFINE-1 PMID 40544433; Davies 2025 NEJM REDEFINE-2 PMID 40544432).

Regulatory and posture

Categories
Metabolic, Fat Loss
Aliases
AM833, Long-acting amylin analog (monotherapy)
Evidence posture
human - Phase 2 monotherapy data published; the active Phase 3 development is the cagrilintide + semaglutide combination (CagriSema), not cagrilintide alone.
Regulatory status
Investigational as a monotherapy. Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. The pivotal Phase 3 evidence is now in the combination product CagriSema (REDEFINE-1 and REDEFINE-2 published 2025 NEJM). There is no FDA-approved cagrilintide-only drug label.
Content review status
investigational verified

Selected public sources

Related tools